Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* a documented hemoglobin level to be less than 10 g/dL at screening~* diagnoses of CKD 4 or 5~* body mass index (BMI) between 18 kg/m2 and 42 kg/m2, inclusive, based upon the height and weight at screening~* ferritin levels ≥100 ng/ml or Tsat ≥20% at screening~* erythropoietin (EPO) level greater than 8 ng/mL~* able to provide written informed consent~* able to understand and follow all trial procedures~* willing to use contraception as detailed in the protocol~Exclusion Criteria:~* receipt of red blood cell (RBC) transfusion within four weeks before screening~* overt gastrointestinal bleeding or other bleeding episode that required transfusion within 2 months prior to screening~* infection necessitating antibiotic or anti-viral treatment within a month prior to screening~* requiring Coumadin (warfarin), Pradaxa®, Eliquis®, or Xarelto®~* hemoglobinopathies such as homozygous sickle-cell disease or thalassemias of all types~* active hemolysis or chronic hypoxia~* active malignant diseases (except non-melanoma skin cancer) or life expectancy less than 6 months~* chronic, uncontrolled or symptomatic inflammatory disease or non-renal cause of anemia such as rheumatoid arthritis, systemic lupus erythematosus, HIV, or systemic acute infection~* on immunosuppressive therapeutics except topical corticosteroids or nasal sprays~* chronic congestive heart failure (New York Heart Association Class III, IV)~* significant hypertension (≥90 diastolic) based on a sitting diastolic blood pressure at screening~* kidney transplant within the past year: patients who are off immunosuppressive agents following a failed transplant are eligible for the trial~* end-stage liver disease~* known hypersensitivity to recombinant protein therapies~* female patients who are pregnant or breast feeding~* previous exposure to FMX-8~* previous exposure to Epogen®, Procrit® (erythropoietin) Aranesp® (darbepoietin alpha), Omontys® or Hematide® (peginesatide) anemia treatment~* uncontrolled hyperparathyroidism (PTH \>750) based upon latest PTH determination within the past 4 months~* inability to comply with the trial scheduled visits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMX-8 (Type: OTHER): FMX-8 for injection, 15mg/kg, twice weekly, 29 days

Based on this trial design, predict the completion outcome and termination type (if applicable).